Lowest Price Guaranteed
Pages
325
Last Updated
August 2026
View Count
28275
1. PREFACE
1.1. Oligonucleotide Synthesis Market Overview
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating The Risks Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
4.1. Chapter Overview
5. INTRODUCTION
5.1. Chapter Overview
5.2. Oligonucleotide Structure
5.3. Types of Oligonucleotides
5.3.1. Antisense Oligonucleotides
5.3.2. Aptamers
5.3.3. miRNA
5.3.4. shRNA
5.3.5. siRNA
5.3.6. Other Oligonucleotides
5.4. Manufacturing of Oligonucleotides
5.4.1. Synthesis of Oligonucleotides
5.4.1.1. Process Development / Validation
5.4.1.2. Analytical Testing
5.4.1.3. Quality Control and Quality Assurance
5.4.2. Modification of Oligonucleotides
5.4.2.1. Backbone Modification
5.4.2.2. Sugar Ring Modification
5.4.3. Purification of Oligonucleotides
5.4.3.1. Cartridge Purification
5.4.3.2. Desalting
5.4.3.3. High Performance Liquid Chromatography
5.4.3.4. Polyacrylamide Gel Electrophoresis
5.4.4 Formulation of Oligonucleotides
5.5. Outsourcing Oligonucleotide Manufacturing
5.5.1. Need for Outsourcing
5.5.2. Advantages of Outsourcing Manufacturing Operations
5.6. Future Perspectives
6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Oligonucleotide Synthesis Providers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Company Size and Location of Headquarters
6.2.5. Analysis by Location of Oligonucleotide Synthesis Facilities
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Type of Oligonucleotide Synthesized
6.2.8. Analysis by Type of Oligonucleotide Product Synthesized
6.2.9. Analysis by Application Area
6.2.10. Analysis by Type of Additional Service Offered
7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Oligonucleotide Synthesis Providers: Company Competitiveness Analysis
7.4.1. Oligonucleotide Synthesis Providers Based in North America
7.4.2. Oligonucleotide Synthesis Providers Based in Europe
7.4.3. Oligonucleotide Synthesis Providers Based in Asia- Pacific and Rest of the World
8. COMPANY PROFILES
8.1. Chapter Overview
8.2. Detailed Company Profiles of Leading Service Providers
8.2.1. Agilent Technologies
8.2.1.1. Company Overview
8.2.1.2. Financial Information
8.2.1.3. Service Portfolio
8.2.1.4. Recent Developments and Future Outlook
8.2.2. Ajinomoto Bio-Pharma Services
8.2.2.1. Company Overview
8.2.2.2. Financial Information
8.2.2.3. Service Portfolio
8.2.2.4. Recent Developments and Future Outlook
8.2.3. CordenPharma
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio
8.2.3.3. Recent Developments and Future Outlook
8.2.4. Integrated DNA Technologies
8.2.4.1. Company Overview
8.2.4.2. Service Portfolio
8.2.4.3. Recent Developments and Future Outlook
8.2.5. Kaneka Eurogentec
8.2.5.1. Company Overview
8.2.5.2. Financial Information
8.2.5.3. Service Portfolio
8.2.5.4. Recent Developments and Future Outlook
8.2.6. LGC Biosearch Technologies
8.2.6.1. Company Overview
8.2.6.2. Financial Information
8.2.6.3. Service Portfolio
8.2.6.4. Recent Developments and Future Outlook
8.2.7. Microsynth
8.2.7.1. Company Overview
8.2.7.2. Service Portfolio
8.2.7.3. Recent Developments and Future Outlook
8.2.8. Merck
8.2.8.1. Company Overview
8.2.8.2. Financial Information
8.2.8.3. Service Portfolio
8.2.8.4. Recent Developments and Future Outlook
8.2.9. Nitto Avecia
8.2.9.1. Company Overview
8.2.9.2. Financial Information
8.2.9.3. Service Portfolio
8.2.9.4. Recent Developments and Future Outlook
8.2.10. Thermo Fisher Scientific
8.2.10.1. Company Overview
8.2.10.2. Financial Information
8.2.10.3. Service Portfolio
8.2.10.4. Recent Developments and Future Outlook
8.2.11. TriLink BioTechnologies
8.2.11.1. Company Overview
8.2.11.2. Service Portfolio
8.2.11.3. Recent Developments and Future Outlook
8.3. Short Company Profiles of Leading Service Providers
8.3.1. Creative Biolabs
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.2. Ella Biotech
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.3. Eurofins Genomics
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.4. Future Synthesis
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio
8.3.5. Ribo Biotechnology
8.3.5.1. Company Overview
8.3.5.2. Service Portfolio
8.3.6. STA Pharmaceutical
8.3.6.1. Company Overview
8.3.6.2. Service Portfolio
8.3.7. Sumitomo Chemical
8.3.7.1. Company Overview
8.3.7.2. Service Portfolio
9. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Oligonucleotide Synthesis: Make versus Buy Decision Making Framework
9.3.1. Scenario 1
9.3.2. Scenario 2
9.3.3. Scenario 3
9.3.4. Scenario 4
9.4. Concluding Remarks
10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Oligonucleotide Therapeutics: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Registration Year and Trial Status
10.3.4. Analysis by Trial Phase
10.3.5. Analysis by Trial Registration Year and Trial Phase
10.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
10.3.7. Analysis of Enrolled Patient Population by Trial Phase
10.3.8. Analysis by Type of Oligonucleotide
10.3.9. Analysis by Therapeutic Area
10.3.10. Analysis by Study Design
10.3.11. Analysis by Type of Sponsor
10.3.12. Most Active Players: Analysis by Number of Registered Trials
10.3.13. Analysis of Number of Registered Trials by Geography
10.3.14. Analysis of Number of Registered Trials by Trial Status and Geography
10.3.15. Analysis of Enrolled Patient Population by Geography
10.3.16. Analysis of Enrolled Patient Population by Trial Status and Geography
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Oligonucleotide Synthesis: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Oligonucleotide
11.3.5. Analysis by Therapeutic Area
11.3.6. Analysis by Application Area
11.3.7. Most Active Players: Analysis by Number of Partnerships
11.3.8. Analysis by Geography
11.3.8.1. Intracontinental and Intercontinental Agreements
11.3.8.2. Local and International Agreements
12. RECENT EXPANSIONS
12.1. Chapter Overview
12.2. Type of Expansion
12.3. Oligonucleotide Synthesis: Recent Expansions
12.3.1. Analysis by Year of Expansion
12.3.2. Analysis by Type of Expansion
12.3.3. Analysis by Year and Type of Expansion
12.3.4. Analysis by Location of Expanded Facility
12.3.5. Analysis by Type of Expansion and Location of Expanded Facility
12.3.6. Analysis by Area of Expanded Facility
12.3.7. Analysis by Scale of Operation
12.3.8. Analysis by Amount Invested
12.3.9. Most Active Players: Analysis by Number of Expansions
13. BIG PHARMA INITIATIVES
13.1. Chapter Overview
13.2. Oligonucleotide Related Initiatives by Big Pharmaceutical Players
13.2.1. Analysis by Number of Initiatives
13.2.2. Analysis by Year of Initiative
13.2.3. Analysis by Type of Initiative
13.2.3.1. Analysis by Type of Partnership
13.2.3.2. Analysis by Type of Expansion
13.2.4. Analysis by Year and Type of Initiative
13.2.5. Analysis by Scale of Operation
13.2.6. Analysis by Type of Oligonucleotide
13.2.7. Analysis by Amount Invested
14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Oligonucleotide Synthesis: Global Installed Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Geography
14.3.2.1. Analysis of Oligonucleotide Synthesis Capacity in North America
14.3.2.2. Analysis of Oligonucleotide Synthesis Capacity in Europe
14.3.2.3. Analysis of Oligonucleotide Synthesis Capacity in Asia-Pacific and Rest of the World
14.3.3. Concluding Remarks
15. DEMAND ANALYSIS
15.1 Chapter Overview
15.2. Assumptions and Methodology
15.3. Overall Demand for Oligonucleotides
15.4. Global Clinical Demand for Oligonucleotides
15.4.1. Analysis by Type of Oligonucleotide
15.4.2. Analysis by Therapeutic Area
15.4.3. Analysis by Geography
15.5. Global Commercial Demand for Oligonucleotides
15.5.1. Analysis by Type of Oligonucleotide
15.5.2. Analysis by Therapeutic Area
15.5.3. Analysis by Geography
16. MARKET IMPACT ANALYSIS
16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion
17. GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Global Oligonucleotide Synthesis Market, Historical Trends (2018-2023) and Future Estimates (2024-2035)
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario
17.4. Key Market Segmentations
18. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION AREA
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Oligonucleotide Synthesis Market: Distribution by Application Area, 2018, 2024 and 2035
18.3.1. Research and Diagnostics: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.2. Therapeutics: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.4. Data Triangulation and Validation
19. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE OF PRODUCT SYNTHESIZED
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Oligonucleotide Synthesis Market: Distribution by Type of Product Synthesized, 2018, 2024 and 2035
19.3.1. Active Pharmaceutical Ingredients: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.2. Finished Dosage Forms: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.4. Data Triangulation and Validation
20. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE OF OLIGONUCLEOTIDE SYNTHESIZED
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Oligonucleotide Synthesis Market: Distribution by Type of Oligonucleotide Synthesized, 2018, 2024 and 2035
20.3.1. Antisense Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
20.3.2. DNA Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
20.3.3. siRNA Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
20.3.4. Other Oligonucleotides: Historical Trends (2018-2023) and Future Estimates (2024-2035)
20.4. Data Triangulation and Validation
21. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY SCALE OF OPERATION
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Oligonucleotide Synthesis Market: Distribution by Scale of Operation, 2018, 2024 and 2035
21.3.1. Clinical Scale of Operation: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.2. Commercial Scale of Operation: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.4. Data Triangulation and Validation
22. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY THERAPEUTIC AREA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Oligonucleotide Synthesis Market: Distribution Therapeutic Area, 2018, 2024 and 2035
22.3.1. Cardiovascular Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
22.3.2. Genetic Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
22.3.3. Liver Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
22.3.4. Rare Diseases: Historical Trends (2018-2023) and Future Estimates (2024-2035)
22.3.5. Other Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
22.4. Data Triangulation and Validation
23. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END-USERS
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Oligonucleotide Synthesis Market: Distribution by End-users, 2018, 2024 and 2035
23.3.1. Pharmaceutical / Biopharmaceutical Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
23.3.2. Academic and Research Institutes: Historical Trends (2018-2023) and Future Estimates (2024-2035)
23.3.3. Hospitals: Historical Trends (2018-2023) and Future Estimates (2024-2035)
23.4. Data Triangulation and Validation
24. OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COMPANY SIZE
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Oligonucleotide Synthesis Market: Distribution by Company Size, 2018, 2024 and 2035
24.3.1. Small Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
24.3.2. Mid-sized Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
24.3.3. Large and Very Large Companies: Historical Trends (2018-2023) and Future Estimates (2024-2035)
24.4. Data Triangulation and Validation
25. OLIGONUCLEOTIDE SYNTHESIS MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Oligonucleotide Synthesis Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
25.3.1. North America: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.1.1. US: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.1.2. Canada: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2. Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2.1. Switzerland: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2.2. Germany: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2.3. Belgium: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.2.4. Rest of Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3. Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.1. China: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.2. South Korea: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.3. Japan: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.4. India: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.3.5. Rest of Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.3.4. Rest of the World: Historical Trends (2018-2023) and Future Estimates (2024-2035)
25.4. Data Triangulation and Validation
26. EXECUTIVE INSIGHTS
26.1. Chapter Overview
26.2. BianoGMP
26.2.1. Company Snapshot
26.2.2. Interview Transcript
26.3. Hanugen Therapeutics
26.3.1. Company Snapshot
26.3.2. Interview Transcript
26.4. IBA Life Sciences
26.4.1. Company Snapshot
26.4.2 Interview Transcript
26.5. Axolabs
26.5.1. Company Snapshot
26.5.2. Interview Transcript
26.6. SBS Genetech
26.6.1. Company Snapshot
26.6.2. Interview Transcript
26.7. Aptagen
26.7.1. Company Snapshot
26.7.2. Interview Transcript
26.8. Invitek Diagnostics
26.8.1. Company Snapshot
26.8.2. Interview Transcript
27. CONCLUDING REMARKS
27.1. Chapter Overview
28. APPENDIX I: TABULATED DATA
29. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION
Figure 2.1 Research Methodology: Research Assumptions
Figure 2.2 Research Methodology: Project Methodology
Figure 2.3 Research Methodology: Forecast Methodology
Figure 2.4 Research Methodology: Robust Quality Control
Figure 2.5 Research Methodology: Key Market Segmentations
Figure 4.1. Executive Summary: Overall Market Landscape (I/II)
Figure 4.2. Executive Summary: Overall Market Landscape (II/II)
Figure 4.3. Executive Summary: Clinical Trial Analysis
Figure 4.4. Executive Summary: Partnerships and Collaborations
Figure 4.5. Executive Summary: Recent Expansions
Figure 4.6. Executive Summary: Big Pharma Initiatives
Figure 4.7. Executive Summary: Capacity Analysis
Figure 4.8. Executive Summary: Demand Analysis
Figure 4.9. Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1. Classification of Oligonucleotides
Figure 5.2. Steps Involved in the Oligonucleotide Manufacturing
Figure 5.3. Types of Modifications of Oligonucleotides
Figure 5.4. Types of Purification Methods Used for Oligonucleotides
Figure 5.5. Commonly Outsourced Oligonucleotide Manufacturing Services
Figure 6.1. Oligonucleotide SynthesisProviders: Distribution by Year of Establishment
Figure 6.2. Oligonucleotide SynthesisProviders: Distribution by Company Size
Figure 6.3. Oligonucleotide SynthesisProviders: Distribution by Location of Headquarters
Figure 6.4. Oligonucleotide SynthesisProviders: Distribution by Company Size and Location of Headquarters
Figure 6.5. Oligonucleotide SynthesisProviders: Distribution by Location of Oligonucleotide Synthesis Facilities
Figure 6.6. Oligonucleotide SynthesisProviders: Distribution by Scale of Operation
Figure 6.7. Oligonucleotide SynthesisProviders: Distribution by Type of Oligonucleotide Synthesized
Figure 6.8. Oligonucleotide SynthesisProviders: Distribution by Type of ProductSynthesized
Figure 6.9. Oligonucleotide SynthesisProviders: Distribution by Application Area
Figure 6.10. Oligonucleotide Synthesis Providers: Distribution by Type of Additional Services Offered
Figure 7.1. Company CompetitivenessAnalysis: Oligonucleotide Synthesis Providers based in North America
Figure 7.2. Company CompetitivenessAnalysis: Oligonucleotide Synthesis Providers based in Europe
Figure 7.3. Company CompetitivenessAnalysis: Oligonucleotide Synthesis Providers based in Asia-Pacific and Rest of the World
Figure 8.1. Agilent Technologies: AnnualRevenues, FY 2018-FY 2023 (USD Billion)
Figure 8.2. Ajinomoto Bio-PharmaServices: Annual Revenues, FY 2019-H1 FY 2023 (YEN Billion)
Figure 8.3. Kaneka: Annual Revenues, FY2019-Q1 FY 2023 (YEN Billion)
Figure 8.4. LGC Group: Annual Revenues,FY 2019-FY 2023 (GBP Million)
Figure 8.5. Merck: Annual Revenues, FY2019-9M FY 2023 (EUR Billion)
Figure 8.6. Nitto Avecia: AnnualRevenues, FY 2019-H1 FY 2023 (YEN Billion)
Figure 8.7. Thermo Fisher Scientific:Annual Revenues, FY 2019-9M FY 2023 (USD Billion)
Figure 9.1. Make versus Buy Decision Making Framework
Figure 9.2. Make versus Buy Decision Making: Possible Scenarios
Figure 10.1. Clinical Trial Analysis: Scopeand Methodology
Figure 10.2. Clinical Trial Analysis:Cumulative Year-wise Trend, Pre-2015-2023
Figure 10.3. Clinical Trial Analysis:Distribution by Trial Status
Figure 10.4. Clinical Trial Analysis:Distribution by Trial Registration Year and Trial Status, 2015-2023
Figure 10.5. Clinical Trial Analysis:Distribution by Trial Phase
Figure 10.6. Clinical Trial Analysis:Distribution by Trial Registration Year and Trial Phase, Pre-2007 - Post-2018
Figure 10.7. Clinical Trial Analysis:Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2015-2023
Figure 10.8. Clinical Trial Analysis:Distribution of Enrolled Patient Population by Trial Phase
Figure 10.9. Clinical Trial Analysis: Distribution by Type of Oligonucleotide
Figure 10.10. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.11. Clinical Trial Analysis: Distribution by Study Design
Figure 10.12. Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 10.13. Most Active Players: Distribution by Number of Registered Trials
Figure 10.14. Clinical Trial Analysis: Distribution of Registered Trials by Geography
Figure 10.15. Clinical Trial Analysis: Distribution of Registered Trials by Trial Status and Geography
Figure 10.16. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 10.17. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 11.1. Partnerships andCollaborations: Cumulative Year-wise Trend, 2014-2023
Figure 11.2. Partnerships andCollaborations: Distribution by Type of Partnership
Figure 11.3. Partnerships andCollaborations: Distribution by Year and Type of Partnership
Figure 11.4. Partnerships andCollaborations: Distribution by Type of Oligonucleotide
Figure 11.5. Partnerships andCollaborations: Distribution by Therapeutic Area
Figure 11.6. Partnerships andCollaborations: Distribution by Application Area
Figure 11.7. Most Active Players:Distribution by Number of Partnerships
Figure 11.8. Partnerships andCollaborations: Intracontinental and Intercontinental Agreements
Figure 11.9. Partnerships andCollaborations: Local and International Agreements
Figure 12.1. Recent Expansions:Cumulative Year-wise Trend, 2015-2023
Figure 12.2. Recent Expansions:Distribution by Type of Expansion
Figure 12.3. Recent Expansions:Distribution by Year and Type of Expansion
Figure 12.4. Recent Expansions:Distribution by Location of Expanded Facility
Figure 12.5. Recent Expansions:Distribution by Type of Expansion and Location of Expanded Facility
Figure 12.6. Recent Expansions:Distribution by Area of Expanded Facility (sq. ft.)
Figure 12.7. Recent Expansions:Distribution by Scale of Operation
Figure 12.8. Recent Expansions:Distribution by Amount Invested (USD Million)
Figure 12.9. Most Active Players:Distribution by Number of Recent Expansions
Figure 13.1. Big Pharma Initiatives:Distribution by Number of Initiatives
Figure 13.2. Big Pharma Initiatives:Distribution by Year of Initiative, Pre-2020-2023
Figure 13.3. Big Pharma Initiatives:Distribution by Type of Initiative
Figure 13.4. Big Pharma Initiatives:Distribution by Type of Partnership
Figure 13.5. Big Pharma Initiatives:Distribution by Type of Expansion
Figure 13.6. Big Pharma Initiatives:Distribution by Year and Type of Initiative
Figure 13.7. Big Pharma Initiatives:Distribution by Scale of Operation
Figure 13.8. Big Pharma Initiatives:Distribution by Type of Oligonucleotide
Figure 13.9. Big Pharma Initiatives:Distribution by Amount Invested (USD Million)
Figure 14.1. Capacity Analysis: Distribution by Company Size
Figure 14.2. Capacity Analysis: Distribution by Location of Synthesis Facility
Figure 14.3. Distribution ofOligonucleotide Synthesis Capacity in North America
Figure 14.4. Distribution ofOligonucleotide Synthesis Capacity in Europe
Figure 14.5. Distribution ofOligonucleotide Synthesis Capacity in Asia-Pacific and Rest of the World
Figure 15.1. Overall Demand for Oligonucleotides, 2024-2035 (in kilograms)
Figure 15.2. Global Clinical Demand for Oligonucleotides, 2024-2035 (in kilograms)
Figure 15.3. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
Figure 15.4. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
Figure 15.5. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
Figure 15.6. Global Commercial Demand for Oligonucleotides, 2024-2035 (in kilograms)
Figure 15.7. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
Figure 15.8. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
Figure 15.9. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
Figure 16.1. Oligonucleotide Synthesis: Market Drivers
Figure 16.2. Oligonucleotide Synthesis: Market Restraints
Figure 16.3. Oligonucleotide Synthesis: Market Opportunities
Figure 16.4. Oligonucleotide Synthesis: Market Challenges
Figure 17.1. Global Oligonucleotide Synthesis Market, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 17.2. Global Oligonucleotide Synthesis Market, 2024-2035: Conservative Scenario (USD Billion)
Figure 17.3. Oligonucleotide Synthesis Market, 2024-2035: Optimistic Scenario (USD Billion)
Figure 18.1. Oligonucleotide Synthesis Market: Distribution by Application Area, 2018, 2024 and 2035 (USD Billion)
Figure 18.2. Oligonucleotide Synthesis Market for Research and Diagnostics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 18.3. Oligonucleotide Synthesis Market for Therapeutics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.1. Oligonucleotide Synthesis Market: Distribution by Type of Product Synthesized, 2018, 2024 and 2035 (USD Billion)
Figure 19.2. Oligonucleotide Synthesis Market for Active Pharmaceutical Ingredients, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 19.3. Oligonucleotide Synthesis Market for Finished Dosage Forms, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.1. Oligonucleotide Synthesis Market: Distribution by Type of Oligonucleotide Synthesized, 2018, 2024 and 2035 (USD Billion)
Figure 20.2. Oligonucleotide Synthesis Market for Antisense Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.3. Oligonucleotide Synthesis Market for DNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.4. Oligonucleotide Synthesis Market for siRNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 20.5. Oligonucleotide Synthesis Market for Other Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.1. Oligonucleotide Synthesis Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Billion)
Figure 21.2. Oligonucleotide Synthesis Market for Commercial Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 21.3 Oligonucleotide Synthesis for Clinical Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.1. Oligonucleotide Synthesis Market: Distribution by Therapeutic Area, 2018, 2024 and 2035 (USD Billion)
Figure 22.2. Oligonucleotide Synthesis Market for Rare Diseases, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.3. Oligonucleotide Synthesis Market for Liver Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.4. Oligonucleotide Synthesis Market for Genetic Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.5. Oligonucleotide Synthesis Market for Cardiovascular Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 22.6. Oligonucleotide Synthesis Market for Other Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 23.1. Oligonucleotide Synthesis Market: Distribution by End-users, 2018, 2024 and 2035 (USD Billion)
Figure 23.2. Oligonucleotide Synthesis Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 23.3. Oligonucleotide Synthesis Market for Academic and Research Institutes, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 23.4. Oligonucleotide Synthesis Market for Hospitals, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 24.1. Oligonucleotide Synthesis Market: Distribution by Company Size, 2018, 2024 and 2035 (USD Billion)
Figure 24.2. Oligonucleotide Synthesis Market for Large and Very Large Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 24.3. Oligonucleotide Synthesis Market for Mid-sized Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 24.4. Oligonucleotide Synthesis Market for Small Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.1. Oligonucleotide Synthesis Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Billion)
Figure 25.2. Oligonucleotide Synthesis Market in North America, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.3 Oligonucleotide Synthesis Market in the US, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.4 Oligonucleotide Synthesis Market in Canada, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.5. Oligonucleotide Synthesis Market in Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.6 Oligonucleotide Synthesis Market in Switzerland, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.7 Oligonucleotide Synthesis Market in Germany, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.8 Oligonucleotide Synthesis Market in Belgium, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.9. Oligonucleotide Synthesis Market in Rest of Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.10 Oligonucleotide Synthesis Market in Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.11 Oligonucleotide Synthesis Market in China, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Figure 25.12 Oligonucleotide Synthesis Market in South Korea, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Figure 25.13 Oligonucleotide Synthesis Market in Japan, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Figure 25.14 Oligonucleotide Synthesis Market in India, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Figure 25.15 Oligonucleotide SynthesisMarket in Rest of Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 25.16 Oligonucleotide SynthesisMarket in Rest of the World, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Figure 27.1. Concluding Remarks: Oligonucleotide Synthesis: Overall Market Landscape
Figure 27.2. Concluding Remarks: Oligonucleotide Synthesis: Clinical Trial Analysis
Figure 27.3. Concluding Remarks: Oligonucleotide Synthesis: Partnerships and Collaborations
Figure 27.4. Concluding Remarks: Oligonucleotide Synthesis: Recent Expansions
Figure 27.5. Concluding Remarks: Oligonucleotide Synthesis: Big Pharma Initiatives
Figure 27.6. Concluding Remarks: Oligonucleotide Synthesis: Capacity Analysis
Figure 27.7. Concluding Remarks: Oligonucleotide Synthesis: Demand Analysis
Figure 27.8. Concluding Remarks:Oligonucleotide Synthesis: Market Sizing and Opportunity Analysis (I/II)
Figure 27.9. Concluding Remarks:Oligonucleotide Synthesis: Market Sizing and Opportunity Analysis (II/II)
Table 6.1. List of Oligonucleotide Synthesis Providers
Table 6.2. Oligonucleotide Synthesis Providers: Information on Scale of Operation and Type of Oligonucleotide Synthesized
Table 6.3. Oligonucleotide Synthesis Providers: Information on Type of Product Synthesized and Application
Table 6.4. Oligonucleotide SynthesisProviders: Information on Type of Additional Services Offered
Table 8.1. Oligonucleotide Synthesis: Listof Service Providers Profiled
Table 8.2. Agilent Technologies: CompanySnapshot
Table 8.3. Agilent Technologies: ServicePortfolio
Table 8.4. Agilent Technologies: RecentDevelopments and Future Outlook
Table 8.5. Ajinomoto Bio-PharmaServices: Company Snapshot
Table 8.6. Ajinomoto Bio-PharmaServices: Service Portfolio
Table 8.7. Ajinomoto Bio-PharmaServices: Recent Developments and Future Outlook
Table 8.8. CordenPharma: CompanySnapshot
Table 8.9. CordenPharma: ServicePortfolio
Table 8.10. CordenPharma: RecentDevelopments and Future Outlook
Table 8.11. Integrated DNA Technologies:Company Snapshot
Table 8.12. Integrated DNA Technologies:Service Portfolio
Table 8.13. Integrated DNA Technologies:Recent Developments and Future Outlook
Table 8.14. Kaneka Eurogentec: CompanySnapshot
Table 8.15. Kaneka Eurogentec: ServicePortfolio
Table 8.16. LGC Biosearch Technologies:Company Snapshot
Table 8.17. LGC BioresearchTechnologies: Service Portfolio
Table 8.18. LGC Biosearch Technologies:Recent Developments and Future Outlook
Table 8.19. Microsynth: CompanySnapshot
Table 8.20. Microsynth: Service Portfolio
Table 8.21. Merck: Company Snapshot
Table 8.22. Merck: Service Portfolio
Table 8.23. Merck: Recent Developmentsand Future Outlook
Table 8.24. Nitto Avecia: CompanySnapshot
Table 8.25. Nitto Avecia: Service Portfolio
Table 8.26. Nitto Avecia: RecentDevelopments and Future Outlook
Table 8.27. Thermo Fisher Scientific:Company Snapshot
Table 8.28. Thermo Fisher Scientific:Service Portfolio
Table 8.29. Thermo Fisher Scientific:Recent Developments and Future Outlook
Table 8.30. TriLink BioTechnologies: Company Snapshot
Table 8.31. TriLink BioTechnologies:Service Portfolio
Table 8.32. Creative Biolabs: CompanySnapshot
Table 8.33. Creative Biolabs: ServicePortfolio
Table 8.34. Ella Biotech: CompanySnapshot
Table 8.35. Ella Biotech: Service Portfolio
Table 8.36. Eurofins Genomics: CompanySnapshot
Table 8.37. Eurofins Genomics: ServicePortfolio
Table 8.38. Future Synthesis: CompanySnapshot
Table 8.39. Future Synthesis: ServicePortfolio
Table 8.40. Ribo Biotechnology: CompanySnapshot
Table 8.41. Ribo Biotechnology: ServicePortfolio
Table 8.42. STA Pharmaceutical: CompanySnapshot
Table 8.43. STA Pharmaceutical: ServicePortfolio
Table 8.44. Sumitomo Chemical: CompanySnapshot
Table 8.45. Sumitomo Chemical: ServicePortfolio
Table 11.1. Oligonucleotide Synthesis: List of Partnerships and Collaborations, 2014-2023
Table 11.2. Partnerships andCollaborations: Information on Type of Oligonucleotide, Therapeutic Area and Application Area
Table 12.1. Oligonucleotide Synthesis: Listof Recent Expansions
Table 13.1. Oligonucleotide Synthesis: Listof Big Pharma Initiatives
Table 13.2. Big Pharma Initiatives:Information on Type of Oligonucleotide and Amount Invested
Table 14.1. Capacity Analysis: Informationon Total Capacity (Sample Data Set)
Table 14.2. Capacity Analysis: Informationon Average Capacity by Company Size (Sample Dataset)
Table 14.3. Global InstalledOligonucleotide Synthesis Capacity: Total Capacity by Company Size (mmol)
Table 15.1 Global Clinical Demand for Oligonucleotide Synthesis: Information on Number of Enrolled Patients and Trial Phase
Table 15.2 Global Commercial Demand for Oligonucleotide Synthesis: List of Oligonucleotide-based Products
Table 24.1. BianoGMP: Company Snapshots
Table 24.2. Hanugen Therapeutics: Company Snapshots
Table 24.3. IBA Life Sciences: Company Snapshots
Table 24.4. Axolabs: Company Snapshots
Table 24.5. SBS Genetech: Company Snapshots
Table 24.6. Aptagen: Company Snapshots
Table 24.7. Invitek Diagnostics: Company Snapshots
Table 28.1. Oligonucleotide SynthesisProviders: Distribution by Year of Establishment
Table 28.2. Oligonucleotide SynthesisProviders: Distribution by Company Size
Table 28.3. Oligonucleotide SynthesisProviders: Distribution by Location of Headquarters
Table 28.4. Oligonucleotide SynthesisProviders: Distribution by Company Size and Location of Headquarters
Table 28.5. Oligonucleotide SynthesisProviders: Distribution by Location of Oligonucleotide Synthesis Facilities
Table 28.6. Oligonucleotide SynthesisProviders: Distribution by Scale of Operation
Table 28.7. Oligonucleotide SynthesisProviders: Distribution by Type of Oligonucleotide Synthesized
Table 28.8. Oligonucleotide SynthesisProviders: Distribution by Type of Product Synthesized
Table 28.9. Oligonucleotide SynthesisProviders: Distribution by Application Area
Table 28.10. Oligonucleotide SynthesisProviders: Distribution by Type of Additional Services Offered
Table 28.11. Agilent Technologies:Annual Revenues, FY 2018-FY 2023 (USD Billion)
Table 28.12. Ajinomoto Bio-PharmaServices: Annual Revenues, FY 2019-H1 FY 2023 (YEN Billion)
Table 28.13. Kaneka: Annual Revenues,FY 2019-Q1 FY 2023 (YEN Billion)
Table 28.14. LGC Group: AnnualRevenues, FY 2019-FY 2023 (GBP Million)
Table 28.15. Merck: Annual Revenues, FY2019-9M FY 2023 (EUR Billion)
Table 28.16. Nitto Avecia: AnnualRevenues, FY 2019-H1 FY 2023 (YEN Billion)
Table 28.17. Thermo Fisher Scientific:Annual Revenues, FY 2019-9M FY 2023 (USD Billion)
Table 28.18. Clinical Trial Analysis:Cumulative Year-wise Trend, Pre-2015-2023
Table 28.19. Clinical Trial Analysis: Distribution by Trial Status
Table 28.20. Clinical Trial Analysis:Distribution by Trial Registration Year and Trial Status, 2015-2023
Table 28.21. Clinical Trial Analysis:Distribution by Trial Phase
Table 28.22. Clinical Trial Analysis:Distribution by Trial Registration Year and Trial Phase, Pre-2007 – 2023
Table 28.23. Clinical Trial Analysis:Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2015-2023
Table 28.24. Clinical Trial Analysis:Distribution of Enrolled Patient Population by Trial Phase
Table 28.25. Clinical Trial Analysis: Distribution by Type of Oligonucleotide
Table 28.26. Clinical Trial Analysis: Distribution by Therapeutic Area
Table 28.27. Clinical Trial Analysis: Distribution by Study Design
Table 28.28. Clinical Trial Analysis: Distribution by Type of Sponsor
Table 28.29. Most Active Players: Distribution by Number of Registered Trials
Table 28.30. Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 28.31. Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
Table 28.32. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 28.33. Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
Table 28.34. Partnerships andCollaborations: Cumulative Year-wise Trend, 2014-2023
Table 28.35. Partnerships andCollaborations: Distribution by Type of Partnership
Table 28.36. Partnerships andCollaborations: Distribution by Year and Type of Partnership
Table 28.37. Partnerships andCollaborations: Distribution by Type of Oligonucleotide
Table 28.38. Partnerships andCollaborations: Distribution by Therapeutic Area
Table 28.39. Partnerships andCollaborations: Distribution by Application Area
Table 28.40. Most Active Players:Distribution by Number of Partnerships
Table 28.41. Partnerships andCollaborations: Intracontinental and Intercontinental Agreements
Figure 28.42 . Partnerships andCollaborations: Local and International Agreements
Table 28.43. Recent Expansions:Cumulative Year-wise Trend, 2015-2023
Table 28.44. Recent Expansions:Distribution by Type of Expansion
Table 28.45. Recent Expansions:Distribution by Year and Type of Expansion
Table 28.46. Recent Expansions:Distribution by Location of Expanded Facility
Table 28.47. Recent Expansions:Distribution by Type of Expansion and Location of Expanded Facility
Table 28.48. Recent Expansions:Distribution by Area of Expanded Facility (sq. ft.)
Table 28.49. Recent Expansions:Distribution by Scale of Operation
Table 28.50. Recent Expansions:Distribution by Amount Invested (USD Million)
Table 28.51. Most Active Players:Distribution by Number of Recent Expansions
Table 28.52. Big Pharma Players:Distribution by Number of Oligonucleotide related Initiatives
Table 28.53. Big Pharma Initiatives:Distribution by Year of Initiative, Pre-2020-2023
Table 28.54. Big Pharma Initiatives:Distribution by Type of Initiative
Table 28.55. Big Pharma Initiatives:Distribution by Type of Partnership
Table 28.56. Big Pharma Initiatives:Distribution by Type of Expansion
Table 28.57. Big Pharma Initiatives:Distribution by Year and Type of Initiative
Table 28.58. Big Pharma Initiatives:Distribution by Scale of Operation
Table 28.59. Big Pharma Initiatives:Distribution by Type of Oligonucleotide
Table 28.60. Big Pharma Initiatives:Distribution by Amount Invested (USD Million)
Table 28.61. Capacity Analysis: Distribution by Company Size
Table 28.62. Capacity Analysis: Distribution by Location of Synthesis Facility
Table 28.63. Distribution of InstalledOligonucleotide Synthesis Capacity in North America
Table 28.64. Distribution ofOligonucleotide Synthesis Capacity in Europe
Table 28.65. Distribution ofOligonucleotide Synthesis Capacity in Asia-Pacific and Rest of the World
Table 28.66. Overall Demand for Oligonucleotides, 2024-2035 (in kilograms)
Table 28.67. Global Clinical Demand for Oligonucleotides, 2024-2035 (in kilograms)
Table 28.68. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
Table 28.69. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
Table 28.70. Global Clinical Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
Table 28.71. Global Commercial Demand for Oligonucleotides, 2024-2035 (in kilograms)
Table 28.72. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Type of Oligonucleotide (in kilograms)
Table 28.73. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Therapeutic Area (in kilograms)
Table 28.74. Global Commercial Demand for Oligonucleotides, 2024-2035: Distribution by Geography (in kilograms)
Table 28.75. Global Oligonucleotide Synthesis Market, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.76. Global Oligonucleotide Synthesis Market, 2024-2035: Conservative Scenario (USD Billion)
Table 28.77. Oligonucleotide Synthesis Market, 2024-2035: Optimistic Scenario (USD Billion)
Table 28.78. Oligonucleotide Synthesis Market: Distribution by Application Area,2018, 2024 and 2035 (USD Billion)
Table 28.79. Oligonucleotide Synthesis Market for Research and Diagnostics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.80. Oligonucleotide Synthesis Market for Therapeutics, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.81. Oligonucleotide Synthesis Market: Distribution by Type of Product Synthesized, 2018, 2024 and 2035 (USD Billion)
Table 28.82. Oligonucleotide Synthesis Market for Active Pharmaceutical Ingredients, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.83. Oligonucleotide Synthesis Market for Finished Dosage Forms, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.84. Oligonucleotide Synthesis Market: Distribution by Type of Oligonucleotide Synthesized, 2018, 2024 and 2035 (USD Billion)
Table 28.85. Oligonucleotide Synthesis Market for Antisense Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.86. Oligonucleotide Synthesis Market for DNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.87. Oligonucleotide Synthesis Market for siRNA Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.88. Oligonucleotide Synthesis Market for Other Oligonucleotides, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.89. Oligonucleotide Synthesis Market: Distribution by Scale of Operation, 2018, 2024 and 2035 (USD Billion)
Table 28.90. Oligonucleotide Synthesis Market for Commercial Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.91. Oligonucleotide Synthesis for Clinical Operations, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.92. Oligonucleotide Synthesis Market: Distribution by Therapeutic Area, 2018, 2024 and 2035 (USD Billion)
Table 28.93. Oligonucleotide Synthesis Market for Rare Diseases, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.94. Oligonucleotide Synthesis Market for Liver Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.95. Oligonucleotide Synthesis Market for Genetic Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.96. Oligonucleotide Synthesis Market for Cardiovascular Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.97. Oligonucleotide Synthesis Market for Other Disorders, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.98. Oligonucleotide Synthesis Market: Distribution by End-users, 2018, 2024 and 2035 (USD Billion)
Table 28.99. Oligonucleotide Synthesis Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.100. Oligonucleotide Synthesis Market for Academic and Research Institutes, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.101. Oligonucleotide Synthesis Market for Hospitals, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.102. OligonucleotideSynthesis Market: Distribution by Company Size, 2018, 2024 and 2035 (USD Billion)
Table 28.103. Oligonucleotide Synthesis Market for Large and Very Large Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.104. Oligonucleotide Synthesis Market for Mid-sized Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.105. Oligonucleotide Synthesis Market for Small Companies, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.106. Oligonucleotide Synthesis Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035 (USD Billion)
Table 28.107. Oligonucleotide Synthesis Market in North America, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.108. Oligonucleotide Synthesis Market in the US, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.109. Oligonucleotide Synthesis Market in Canada, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.110. Oligonucleotide Synthesis Market in Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.111. Oligonucleotide Synthesis Market in Switzerland, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.112. Oligonucleotide Synthesis Market in Germany, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.113. Oligonucleotide Synthesis Market in Belgium, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.114. Oligonucleotide Synthesis Market in Rest of Europe, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.115. Oligonucleotide Synthesis Market in Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.116. Oligonucleotide Synthesis Market in China, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Table 28.117. Oligonucleotide Synthesis Market in South Korea, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Table 28.118. Oligonucleotide Synthesis Market in Japan, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Table 28.119. Oligonucleotide Synthesis Market in India, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion) (USD Billion)
Table 28.120. Oligonucleotide SynthesisMarket in Rest of Asia-Pacific, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Table 28.121. Oligonucleotide SynthesisMarket in Rest of the World, Historical Trends (2018-2023) and Future Estimates (2024-2035) (USD Billion)
Please contact our team for the details on the companies covered.